BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 30170977)

  • 1. Histological and molecular characterization of intrahepatic bile duct cancers suggests an expanded definition of perihilar cholangiocarcinoma.
    Akita M; Sofue K; Fujikura K; Otani K; Itoh T; Ajiki T; Fukumoto T; Zen Y
    HPB (Oxford); 2019 Feb; 21(2):226-234. PubMed ID: 30170977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholangiocarcinoma miscoding in hepatobiliary centres.
    Selvadurai S; Mann K; Mithra S; Bridgewater J; Malik H; Khan SA
    Eur J Surg Oncol; 2021 Mar; 47(3 Pt B):635-639. PubMed ID: 33032867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDM2 Amplification in Intrahepatic Cholangiocarcinomas: Its Relationship With Large-Duct Type Morphology and Uncommon KRAS Mutations.
    Kim SJ; Akita M; Sung YN; Fujikura K; Lee JH; Hwang S; Yu E; Otani K; Hong SM; Zen Y
    Am J Surg Pathol; 2018 Apr; 42(4):512-521. PubMed ID: 29309301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dichotomy in intrahepatic cholangiocarcinomas based on histologic similarities to hilar cholangiocarcinomas.
    Akita M; Fujikura K; Ajiki T; Fukumoto T; Otani K; Azuma T; Itoh T; Ku Y; Zen Y
    Mod Pathol; 2017 Jul; 30(7):986-997. PubMed ID: 28338651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrahepatic cholangiocarcinoma: typical features, uncommon variants, and controversial related entities.
    Zen Y
    Hum Pathol; 2023 Feb; 132():197-207. PubMed ID: 35697170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment and validation of a prognostic nomogram for patients with resectable perihilar cholangiocarcinoma.
    Chen P; Li B; Zhu Y; Chen W; Liu X; Li M; Duan X; Yi B; Wang J; Liu C; Luo X; Li X; Li J; Liang L; Yin X; Wang H; Jiang X
    Oncotarget; 2016 Jun; 7(24):37319-37330. PubMed ID: 27144432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of gene mutations in bile duct cancers: is it time to overcome the anatomical classification?
    Bagante F; Ruzzenente A; Conci S; Rusev BC; Simbolo M; Campagnaro T; Pawlik TM; Luchini C; Iacono C; Scarpa A; Guglielmi A
    HPB (Oxford); 2019 Dec; 21(12):1648-1655. PubMed ID: 31122820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Keratin 19-expressing hepatocellular carcinoma and small-duct type intrahepatic cholangiocarcinoma show a similar postoperative clinical course but have distinct genetic features.
    Akita M; Ajiki T; Fukumoto T; Itoh T; Zen Y
    Histopathology; 2019 Sep; 75(3):385-393. PubMed ID: 31017316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An immunostaining panel of C-reactive protein, N-cadherin, and S100 calcium binding protein P is useful for intrahepatic cholangiocarcinoma subtyping.
    Akita M; Sawada R; Komatsu M; Suleman N; Itoh T; Ajiki T; Heaton N; Fukumoto T; Zen Y
    Hum Pathol; 2021 Mar; 109():45-52. PubMed ID: 33321161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DLEC1 methylation is associated with a better clinical outcome in patients with intrahepatic cholangiocarcinoma of the small duct subtype.
    Kim Y; Lee K; Jeong S; Wen X; Cho NY; Kang GH
    Virchows Arch; 2019 Jul; 475(1):49-58. PubMed ID: 30610381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of the site of portal vein invasion in patients with surgically resected perihilar cholangiocarcinoma.
    Nakanishi Y; Tsuchikawa T; Okamura K; Nakamura T; Tamoto E; Murakami S; Ebihara Y; Kurashima Y; Noji T; Asano T; Shichinohe T; Hirano S
    Surgery; 2016 Jun; 159(6):1511-1519. PubMed ID: 26948498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and external validation of a nomogram for predicting the effect of tumor size on survival of patients with perihilar cholangiocarcinoma.
    Zhang Y; Wu Z; Wang X; Li C; Chang J; Jiang W; Wang H; Wang Y; Li X
    BMC Cancer; 2020 Oct; 20(1):1044. PubMed ID: 33126868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.
    Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D
    BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-33 overexpression reflects less aggressive tumour features in large-duct type cholangiocarcinomas.
    Sawada R; Ku Y; Akita M; Otani K; Fujikura K; Itoh T; Ajiki T; Fukumoto T; Kakeji Y; Zen Y
    Histopathology; 2018 Aug; 73(2):259-272. PubMed ID: 29675965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholangiocarcinoma in Germany: Epidemiologic trends and impact of misclassification.
    Walter D; Ferstl P; Waidmann O; Trojan J; Hartmann S; Schnitzbauer AA; Zeuzem S; Kraywinkel K
    Liver Int; 2019 Feb; 39(2):316-323. PubMed ID: 30176117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinicopathological factors associated with prognosis of patients with resectable perihilar cholangiocarcinoma: A systematic review and meta-analysis.
    Tang Z; Yang Y; Zhao Z; Wei K; Meng W; Li X
    Medicine (Baltimore); 2018 Aug; 97(34):e11999. PubMed ID: 30142840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptomic and histopathological analysis of cholangiolocellular differentiation trait in intrahepatic cholangiocarcinoma.
    Rhee H; Ko JE; Chung T; Jee BA; Kwon SM; Nahm JH; Seok JY; Yoo JE; Choi JS; Thorgeirsson SS; Andersen JB; Lee HS; Woo HG; Park YN
    Liver Int; 2018 Jan; 38(1):113-124. PubMed ID: 28608943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of DNA flow cytometry in distinguishing between malignant and benign intrahepatic biliary lesions.
    Wen KW; Rabinovitch PS; Wang D; Mattis AN; Ferrell LD; Choi WT
    Virchows Arch; 2020 Oct; 477(4):527-534. PubMed ID: 32296928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour stage and overall survival in patients with intrahepatic cholangiocarcinoma and primary sclerosing cholangitis - a retrospective cohort study.
    Schramm C; Sapuk A; Hoyer D; Radünz S; Schmidt H
    Z Gastroenterol; 2024 Jan; 62(1):37-42. PubMed ID: 38195106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C-Reactive Protein (CRP) is a Promising Diagnostic Immunohistochemical Marker for Intrahepatic Cholangiocarcinoma and is Associated With Better Prognosis.
    Yeh YC; Lei HJ; Chen MH; Ho HL; Chiu LY; Li CP; Wang YC
    Am J Surg Pathol; 2017 Dec; 41(12):1630-1641. PubMed ID: 28945626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.